BioCentury | Oct 2, 2020
Finance

3Q20 Wrap: Biotech’s sideways quarter

...Henry, and then in September new CFO Susan Kim.The largest decliner of the group was Satsuma Pharmaceuticals Inc....
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...of the Milken Institute is dedicated to speeding up and improving medical research. Migraine company Satsuma Pharmaceuticals Inc....
...and manage spending. Hongjiang Li, Staff Writer and Robin Sawka, BioCentury Staff Ultragenyx Pharmaceutical Inc. Axsome Therapeutics Inc. ElevateBio LLC Satsuma Pharmaceuticals Inc. WindMIL...
BioCentury | Nov 19, 2019
Financial News

Wellington's first biotech-focused PE fund raises $393M

...the firm participated in a $62 million series B round in April for migraine company Satsuma Pharmaceuticals Inc....
...in a September IPO. Val Kennedy, Associate Editor Wellington Management Moderna Inc. Jounce Therapeutics Inc. Atreca Inc. Arcus Biosciences Inc. CRISPR Therapeutics AG Satsuma Pharmaceuticals Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...HKEX:2696) 09/18/19 $409.9 $3,419.4 $3,341.7 -2% IGM Biosciences Inc. (NASDAQ:IGMS) 09/17/19 $201.3 $385.6 $427.8 11% Satsuma Pharmaceuticals Inc....
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...SpringWorks Therapeutics Inc. (NASDAQ:SWTX) are up $9.82 (55%) to $27.82 from Sept. 12. Shares of Satsuma Pharmaceuticals Inc....
BioCentury | Sep 14, 2019
Financial News

Sept. 13 Financial Quick Takes: Satsuma prices IPO; plus Catalyst scuttles fund-raising and Imara plans a listing

...Satsuma raises $82.5M in NASDAQ listing Migraine company Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) gained $1.90 (13%) to $16.90 after...
...disease (see “OrbiMed, Arix Lead Imara’s $63M B Round” ). Paul Bonanos and Val Kennedy, Associate Editors Satsuma Pharmaceuticals Inc. Catalyst...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...to treat non-Hodgkin lymphoma (NHL). Underwriters are Jefferies, Piper Jaffray, Stifel and Guggenheim. Migraine company Satsuma Pharmaceuticals Inc....
BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

...SpringWorks, Satsuma, Monopar propose IPOs SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and...
...99%. Val Kennedy, Associate Editor and Elizabeth S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. Generex Biotechnology Corp. Monopar Therapeutics Inc. Satsuma Pharmaceuticals Inc....
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

...investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc....
...data from Phase I testing, TPG believes Satsuma's product is best in class. Paul Bonanos, Assistant Editor Satsuma Pharmaceuticals Inc. migraine...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Williams as CSO. Williams was principal scientist at Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP). Migraine company Satsuma Pharmaceuticals Inc....
Items per page:
1 - 10 of 13
BioCentury | Oct 2, 2020
Finance

3Q20 Wrap: Biotech’s sideways quarter

...Henry, and then in September new CFO Susan Kim.The largest decliner of the group was Satsuma Pharmaceuticals Inc....
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...of the Milken Institute is dedicated to speeding up and improving medical research. Migraine company Satsuma Pharmaceuticals Inc....
...and manage spending. Hongjiang Li, Staff Writer and Robin Sawka, BioCentury Staff Ultragenyx Pharmaceutical Inc. Axsome Therapeutics Inc. ElevateBio LLC Satsuma Pharmaceuticals Inc. WindMIL...
BioCentury | Nov 19, 2019
Financial News

Wellington's first biotech-focused PE fund raises $393M

...the firm participated in a $62 million series B round in April for migraine company Satsuma Pharmaceuticals Inc....
...in a September IPO. Val Kennedy, Associate Editor Wellington Management Moderna Inc. Jounce Therapeutics Inc. Atreca Inc. Arcus Biosciences Inc. CRISPR Therapeutics AG Satsuma Pharmaceuticals Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...HKEX:2696) 09/18/19 $409.9 $3,419.4 $3,341.7 -2% IGM Biosciences Inc. (NASDAQ:IGMS) 09/17/19 $201.3 $385.6 $427.8 11% Satsuma Pharmaceuticals Inc....
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...SpringWorks Therapeutics Inc. (NASDAQ:SWTX) are up $9.82 (55%) to $27.82 from Sept. 12. Shares of Satsuma Pharmaceuticals Inc....
BioCentury | Sep 14, 2019
Financial News

Sept. 13 Financial Quick Takes: Satsuma prices IPO; plus Catalyst scuttles fund-raising and Imara plans a listing

...Satsuma raises $82.5M in NASDAQ listing Migraine company Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) gained $1.90 (13%) to $16.90 after...
...disease (see “OrbiMed, Arix Lead Imara’s $63M B Round” ). Paul Bonanos and Val Kennedy, Associate Editors Satsuma Pharmaceuticals Inc. Catalyst...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...to treat non-Hodgkin lymphoma (NHL). Underwriters are Jefferies, Piper Jaffray, Stifel and Guggenheim. Migraine company Satsuma Pharmaceuticals Inc....
BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

...SpringWorks, Satsuma, Monopar propose IPOs SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and...
...99%. Val Kennedy, Associate Editor and Elizabeth S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. Generex Biotechnology Corp. Monopar Therapeutics Inc. Satsuma Pharmaceuticals Inc....
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

...investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc....
...data from Phase I testing, TPG believes Satsuma's product is best in class. Paul Bonanos, Assistant Editor Satsuma Pharmaceuticals Inc. migraine...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Williams as CSO. Williams was principal scientist at Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP). Migraine company Satsuma Pharmaceuticals Inc....
Items per page:
1 - 10 of 13